Woodline Partners LP Ultragenyx Pharmaceutical Inc. Transaction History
Woodline Partners LP
- $11 Billion
- Q3 2024
A detailed history of Woodline Partners LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Woodline Partners LP holds 267,555 shares of RARE stock, worth $12.7 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
267,555
Previous 266,790
0.29%
Holding current value
$12.7 Million
Previous $11 Million
35.54%
% of portfolio
0.13%
Previous 0.11%
Shares
5 transactions
Others Institutions Holding RARE
# of Institutions
322Shares Held
85.5MCall Options Held
668KPut Options Held
288K-
Vanguard Group Inc Valley Forge, PA9.95MShares$474 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$267 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.12MShares$244 Million0.91% of portfolio
-
Wellington Management Group LLP Boston, MA4.17MShares$198 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.07MShares$146 Million0.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.34B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...